Research programme: RNAi cancer therapeutics - Calando

Drug Profile

Research programme: RNAi cancer therapeutics - Calando

Alternative Names: CALAA-02

Latest Information Update: 13 Apr 2016

Price : $50

At a glance

  • Originator Calando Pharmaceuticals; National Cancer Institute (USA)
  • Class Small interfering RNA
  • Mechanism of Action Endothelial PAS domain-containing protein 1 inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer
  • Discontinued Neuroblastoma

Most Recent Events

  • 06 Apr 2016 Arrowhead Research Corporation is now called Arrowhead Pharmaceuticals
  • 02 Mar 2012 Preclinical development is ongoing in USA
  • 03 Feb 2009 Discontinued - Preclinical for Neuroblastoma in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top